Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 4, 1999, Pages 346-357

  Singh, Gur Jai Pal ^a,c   Adams, Wallace P ^a   Lesko, Lawrence J ^a   Shah, Vinod P ^a   Molzon, Justina A ^a   Williams, Roger L ^a   Pershing, Lynn K ^a,b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c Division of Bioequivalence   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCLOMETASONE DIPROPIONATE; BETAMETHASONE VALERATE; CLOBETASOL PROPIONATE; CORTICOSTEROID; FLUOCINONIDE; HYDROCORTISONE; TRIAMCINOLONE ACETONIDE;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DOSE RESPONSE; DRUG POTENCY; HUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SKIN DISEASE; TOPICAL DRUG ADMINISTRATION;

ADRENAL CORTEX HORMONES; BAYES THEOREM; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, THEORETICAL; THERAPEUTIC EQUIVALENCY;

EID: 0032698154     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1053/cp.1999.v66.a101209     Document Type: Article

References (29)

1. 1. 21 Code of Federal Regulations (CFR) 320.24. Types of evidence to establish bioavailability or bioequivalence.
2. 2. Pershing LK, Silver BS, Krueger GG, Shah VP, Skelley JP. Feasibility of measuring the bioavailability of topical betamethasone dipropionate in commercial formulations using drug content in skin and a skin blanching bioassay. Pharm Res 1992;9:45-51.
3. 3. McKenzie AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Arch Dermatol 1962; 86:608-10.
4. 4. Stoughton RB. Vasoconstrictor assay: specific applications. In: Maibach HI, Surber C, editors. Topical corticosteroids. Basel: Karger; 1992. p. 42-53.
5. 5. Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol 1985;121:63-7.
6. 6. Gibson JR, Kirsch JM, Darley CR, Harvey SG, Burke CA, Hanson ME. An assessment of the relationship between vasoconstrictor assay findings, clinical efficacy and skin thinning effects of a variety of undiluted and diluted corticosteroid preparations. Br J Derrnatol 1984; 111(suppl 27):204-12.
7. 7. Barry BW, Woodford R. Comparative bioavailability of proprietary topical corticosteroid preparations: vasoconstrictor assays on thirty creams and gels. Br J Dermatol 1974;91:323-38.
8. 8. Barry BW, Woodford R. Comparative bioavailability and activity of proprietary topical corticosteroid preparations: vasoconstrictor assays on thirty-one ointments. Br J Dermatol 1975;93:563-71.
9. 9. Barry BW, Woodford R. Activity and bioavailability of topical steroids: in vivo/in vitro correlations for the vasoconstrictor test. J Clin Pharm Ther 1978;3:43-65.
10. 10. Haigh JM, Kanfer I. Assessment of topical corticosteroid preparations: the human skin blanching assay. Int J Pharm 1984;19:245-62.
11. 11. Stoughton RB. Are generic formulations equivalent to trade name topical glucocorticoids? Arch Dermatol 1987;123:1312-4.
12. 12. Jackson DB, Thompson C, McCormack JR, Guin JD. Bioequivalence (bioavailability) of generic topical corticosteroids. J Am Acad Dermatol 1989;20:791-6.
13. 13. Olsen EA. A double-blind controlled comparison of generic and trade-name topical steroids using the vasoconstriction assay. Arch Dermatol 1991;127:197-201.
14. 14. Interim guidance, topical corticosteroids: in vivo bioequivalence and in vitro release methods. Division of Bioequivalence and Division of Anti-Infective Drug Products, Center for Drug Evaluation and Research, FDA, Rockville (MD); July 1, 1992.
15. 15. Guidance, topical dermatologic corticosteroids: in vivo bioequivalence. Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, FDA, Rockville (MD); June 2, 1995.
16. 16. Pershing LK, Lambert LD, Shah VP, Lam SY. Variability and correlation of chromameter and tape-stripping methods with the visual skin blanching assay in the quantitative assessment of topical 0.05% betamethasone dipropionate bioavailability in humans. Int J Pharm 1992;86:201-10.
17. 17. Queille-Roussel C, Poncet M, Schaefer H. Quantitation of skin-colour changes induced by topical corticosteroid preparations using the Minolta Chroma Meter. Br J Dermatol 1991;124:264-70.
18. 18. Wagner JG. Pharmacokinetics for the pharmaceutical scientist. Lancaster (PA): Technomic Publishing; 1993.
19. 19. Steimer JL, Mallet A, Mentré F. Estimating interindividual pharmacokinetic variability. In: Rowland M, Sheiner LB, Steimer JL, editors. Variability in drug therapy: description, estimation, and control. New York: Raven; 1985. p. 65-111.
20. 20. Gomeni R, Pineau G, Mentré F. Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package. Anticancer Res 1994;14:2321-6.
21. 21. Kinowski JM, Bressolle F, Rodier M, Augey V, Fahre D, Richard JL, et al. A limited sampling model with Bayesian estimation to determine inulin pharmacokinetics using the population data modelling program P-PHARM. Clin Drug Invest 1995;9:260-9.
22. 22. Guidance, statistical procedures for bioequivalence studies using a standard two-treatment crossover design. Office of Generic Drugs, Center for Drug Evaluation and Research, FDA, Rockville (MD); July 1, 1992.
23. 23. Locke CS. An exact confidence interval from untransformed data for the ratio of two formulation means. J Pharmacokinet Biopharm 1984;12:649-55.
24. 24. Koopmans LH, Owen DB, Rosenblatt JI. Confidence intervals for the coefficient of variation for the normal and log normal distributions. Biometrika 1964;51:25-32.
25. 25. Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981;6:429-53.
26. 26. Holford NHG. Pharmacodynamics. In: Williams RL, Brater DC, Mordenti J, editors. Rational therapeutics: A clinical pharmacologic guide for the health professional. New York: Marcel Dekker; 1990, p. 57-78.
27. 27. Transcript, Generic Drugs Advisory Committee Meeting with Dermatologic Drugs Advisory Committee Representation. Center for Drug Evaluation and Research, FDA. Rockville (MD); September 13, 1994, p. 64-5.
28. 28. Temple RJ. Special study designs: early escape, enrichment, studies in non-responders. Commun Statist Theory Meth 1994;23:499-531.
29. 29. Interim guidance for documentation of in vivo bioequivalence of albuterol inhalation aerosols (metered dose inhalers). Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, FDA, Rockville (MD); January 27, 1994.